NAD(P)H quinone oxidoreductase (NQO1)

An enzyme which needs just enough mobility, in just the right places

Angel L. Pey, Clare F. Megarity, David J. Timson

Research output: Contribution to journalArticleResearchpeer-review

Abstract

NAD(P)H quinone oxidoreductase 1 (NQO1) catalyses the two electron reduction of quinones and a wide range of other organic compounds. Its physiological role is believed to be partly the reduction of free radical load in cells and the detoxification of xenobiotics. It also has non-enzymatic functions stabilising a number of cellular regulators including p53. Functionally, NQO1 is a homodimer with two active sites formed from residues from both polypeptide chains. Catalysis proceeds via a substituted enzyme mechanism involving a tightly bound FAD cofactor. Dicoumarol and some structurally related compounds act as competitive inhibitors of NQO1. There is some evidence for negative cooperativity in quinine oxidoreductases which is most likely to be mediated at least in part by alterations to the mobility of the protein. Human NQO1 is implicated in cancer. It is often over-expressed in cancer cells and as such is considered as a possible drug target. Interestingly, a common polymorphic form of human NQO1, p.P187S, is associated with an increased risk of several forms of cancer. This variant has much lower activity than the wild-type, primarily due to its substantially reduced affinity for FAD which results from lower stability. This lower stability results from inappropriate mobility of key parts of the protein. Thus, NQO1 relies on correct mobility for normal function, but inappropriate mobility results in dysfunction and may cause disease.

Original languageEnglish
Article numberBSR20180459
JournalBioscience Reports
Volume39
Issue number1
DOIs
Publication statusPublished - 3 Jan 2019

Fingerprint

Flavin-Adenine Dinucleotide
NAD
Oxidoreductases
Dicumarol
Quinones
Detoxification
Quinine
Xenobiotics
Enzymes
Organic compounds
Catalysis
Free Radicals
Neoplasms
Proteins
Cells
Peptides
Electrons
Catalytic Domain
Pharmaceutical Preparations
benzoquinone

Bibliographical note

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).

Cite this

@article{c017b518cd834afebdc3c076b9579e8e,
title = "NAD(P)H quinone oxidoreductase (NQO1): An enzyme which needs just enough mobility, in just the right places",
abstract = "NAD(P)H quinone oxidoreductase 1 (NQO1) catalyses the two electron reduction of quinones and a wide range of other organic compounds. Its physiological role is believed to be partly the reduction of free radical load in cells and the detoxification of xenobiotics. It also has non-enzymatic functions stabilising a number of cellular regulators including p53. Functionally, NQO1 is a homodimer with two active sites formed from residues from both polypeptide chains. Catalysis proceeds via a substituted enzyme mechanism involving a tightly bound FAD cofactor. Dicoumarol and some structurally related compounds act as competitive inhibitors of NQO1. There is some evidence for negative cooperativity in quinine oxidoreductases which is most likely to be mediated at least in part by alterations to the mobility of the protein. Human NQO1 is implicated in cancer. It is often over-expressed in cancer cells and as such is considered as a possible drug target. Interestingly, a common polymorphic form of human NQO1, p.P187S, is associated with an increased risk of several forms of cancer. This variant has much lower activity than the wild-type, primarily due to its substantially reduced affinity for FAD which results from lower stability. This lower stability results from inappropriate mobility of key parts of the protein. Thus, NQO1 relies on correct mobility for normal function, but inappropriate mobility results in dysfunction and may cause disease.",
author = "Pey, {Angel L.} and Megarity, {Clare F.} and Timson, {David J.}",
note = "{\circledC} 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).",
year = "2019",
month = "1",
day = "3",
doi = "10.1042/BSR20180459",
language = "English",
volume = "39",
journal = "Bioscience Reports",
issn = "0144-8463",
publisher = "Portland Press Limited",
number = "1",

}

NAD(P)H quinone oxidoreductase (NQO1) : An enzyme which needs just enough mobility, in just the right places. / Pey, Angel L.; Megarity, Clare F.; Timson, David J.

In: Bioscience Reports, Vol. 39, No. 1, BSR20180459, 03.01.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - NAD(P)H quinone oxidoreductase (NQO1)

T2 - An enzyme which needs just enough mobility, in just the right places

AU - Pey, Angel L.

AU - Megarity, Clare F.

AU - Timson, David J.

N1 - © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).

PY - 2019/1/3

Y1 - 2019/1/3

N2 - NAD(P)H quinone oxidoreductase 1 (NQO1) catalyses the two electron reduction of quinones and a wide range of other organic compounds. Its physiological role is believed to be partly the reduction of free radical load in cells and the detoxification of xenobiotics. It also has non-enzymatic functions stabilising a number of cellular regulators including p53. Functionally, NQO1 is a homodimer with two active sites formed from residues from both polypeptide chains. Catalysis proceeds via a substituted enzyme mechanism involving a tightly bound FAD cofactor. Dicoumarol and some structurally related compounds act as competitive inhibitors of NQO1. There is some evidence for negative cooperativity in quinine oxidoreductases which is most likely to be mediated at least in part by alterations to the mobility of the protein. Human NQO1 is implicated in cancer. It is often over-expressed in cancer cells and as such is considered as a possible drug target. Interestingly, a common polymorphic form of human NQO1, p.P187S, is associated with an increased risk of several forms of cancer. This variant has much lower activity than the wild-type, primarily due to its substantially reduced affinity for FAD which results from lower stability. This lower stability results from inappropriate mobility of key parts of the protein. Thus, NQO1 relies on correct mobility for normal function, but inappropriate mobility results in dysfunction and may cause disease.

AB - NAD(P)H quinone oxidoreductase 1 (NQO1) catalyses the two electron reduction of quinones and a wide range of other organic compounds. Its physiological role is believed to be partly the reduction of free radical load in cells and the detoxification of xenobiotics. It also has non-enzymatic functions stabilising a number of cellular regulators including p53. Functionally, NQO1 is a homodimer with two active sites formed from residues from both polypeptide chains. Catalysis proceeds via a substituted enzyme mechanism involving a tightly bound FAD cofactor. Dicoumarol and some structurally related compounds act as competitive inhibitors of NQO1. There is some evidence for negative cooperativity in quinine oxidoreductases which is most likely to be mediated at least in part by alterations to the mobility of the protein. Human NQO1 is implicated in cancer. It is often over-expressed in cancer cells and as such is considered as a possible drug target. Interestingly, a common polymorphic form of human NQO1, p.P187S, is associated with an increased risk of several forms of cancer. This variant has much lower activity than the wild-type, primarily due to its substantially reduced affinity for FAD which results from lower stability. This lower stability results from inappropriate mobility of key parts of the protein. Thus, NQO1 relies on correct mobility for normal function, but inappropriate mobility results in dysfunction and may cause disease.

UR - http://www.scopus.com/inward/record.url?scp=85059471474&partnerID=8YFLogxK

U2 - 10.1042/BSR20180459

DO - 10.1042/BSR20180459

M3 - Article

VL - 39

JO - Bioscience Reports

JF - Bioscience Reports

SN - 0144-8463

IS - 1

M1 - BSR20180459

ER -